Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Partners with Albany VA Institute in Prostate Cancer Marker Study

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies will partner with the Stratton VA Medical Center and Albany Research Institute to study genes and proteins that could be used in developing personalized prostate cancer tests, the Pittsfield, Mass.-based company said today.

The partners will work together to analyze samples from patients who have been diagnosed with prostate cancer, or a precancerous benign condition, searching for genes in protein characteristics that could be used in diagnostic or prognostic tests.

"This collaboration will result in a very unique clinical trial where we will be evaluating how fatty acid synthase (FAS) works to diagnose and predict prostate cancer in very specific populations, such as veterans," Nuclea President and CEO Patrick Muraca said in a statement.

"As the population of Vietnam-era veterans continues to age, they will become increasingly at-risk for prostate cancer," Muraca added. "We are very hopeful that FAS will allow earlier, more accurate diagnosis of patients with this disease, as well as better treatment."

Nuclea said it uses its biorepository of over 150,000 clinical specimens to develop its FAS-based diagnostic tests.

The company also said it has filed for pre-market guidance with the FDA for its prostate cancer monitoring test that shows that FAS levels are predictive of metastatic risk.

Nuclea has three business lines including Nuclea Diagnostic Laboratories, which has developed tests for several cancer types; Nuclea Biomarkers, which performs research into molecular oncology therapeutics and diagnostics; and Nuclea Biotherapeutics.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.